Journal
ALLERGY
Volume 75, Issue 2, Pages 357-369Publisher
WILEY
DOI: 10.1111/all.14011
Keywords
airway epithelial cells; airway remodeling; asthma therapy; chronic inflammation; CSF1; CSF1R; dendritic cells
Categories
Funding
- NIH [R01HL126852, R01 HL137224]
- Dr Ralph and Marian Falk Medical Research Trust Bank of American
- Trustee and Respiratory Health Association Grant [RHA2016-01]
- Research Resource Center (Biophysics Core, Research Histology and Tissue Imaging Core, Flow Cytometry Core) at the University of Illinois at Chicago
Ask authors/readers for more resources
Background A new approach targeting aeroallergen sensing in the early events of mucosal immunity could have greater benefit. The CSF1-CSF1R pathway has a critical role in trafficking allergens to regional lymph nodes through activating dendritic cells. Intervention in this pathway could prevent allergen sensitization and subsequent Th2 allergic inflammation. Objective To examine the therapeutic effectiveness of CSF1 and CSF1R inhibition for blocking the dendritic cell function of sensing aeroallergens. Methods We adopted a model of chronic asthma induced by a panel of three naturally occurring allergens and novel delivery system of CSF1R inhibitor encapsulated nanoprobe. Results Selective depletion of CSF1 in airway epithelial cells abolished the production of allergen-reactive IgE, resulting in prevention of new asthma development as well as reversal of established allergic lung inflammation. CDPL-GW nanoprobe containing GW2580, a selective CSF1R inhibitor, showed favorable pharmacokinetics for inhalational treatment and intranasal insufflation delivery of CDPL-GW nanoprobe ameliorated asthma pathologies including allergen-specific serum IgE production, allergic lung and airway inflammation and airway hyper-responsiveness (AHR) with minimal pulmonary adverse reaction. Conclusion The inhibition of the CSF1-CSF1R signaling pathway effectively suppresses sensitization to aeroallergens and consequent allergic lung inflammation in a murine model of chronic asthma. CSF1R inhibition is a promising new target for the treatment of allergic asthma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available